TG Therapeutics, Inc. Class Action Lawsuit - TGTX

(i) clinical trials revealed significant concerns related to the benefit-risk ratio and overall survival data of the Company's therapeutic product candidates, Ublituximab and Umbralisib; (ii) accordingly, it was unlikely that the Company would be able to obtain approval from the U.S. Food and Drug Administration of the Umbralisib marginal zone lymphoma and follicular lymphoma New Drug Application, the Biologics License Application for Ublituximab in combination with Umbralisib, the supplemental New Drug Application for Ublituximab in combination with Umbralisib, or the Ublituximab relapsing forms of multiple sclerosis Biologics License Application in their current forms; (iii) as a result, the Company had significantly overstated Ublituximab and Umbralisib’s clinical and/or commercial prospects; and (iv) therefore, the Company’s public statements were materially false and misleading at all relevant times.

In order to be eligible to join the TGTX class action lawsuit, you must have incurred a loss on shares of TG Therapeutics purchased during the class period listed above.

If you suffered a loss in TG Therapeutics during the relevant time frame or pursuant to the relevant offering(s), you have until September 16, 2022 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.